esophageal cancer

Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.

PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.

Exome sequences from thousands of Chinese individuals with or without esophageal squamous cell carcinoma led to six new germline risk variants.

Higher levels of oral bacteria like Tannerella forsythia and Porphyromonas gingivalis increased the risk of esophageal cancer, though other bacteria had protective effects.

The team found that cancer-causing genes depend on the BTK gene, which they believe they can shut down with an existing drug.

A new analysis hints that adenocarcinomas or squamous cell carcinomas may have certain overlapping expression patterns, regardless of the tissue of origin.

The five-year award will provide funding for researchers to investigate genetic determinants of Barrett's Esophagus and esophageal adenocarcinoma.